Genmab takes a hit after J&J sounds retreat on cancer combos, as patient deaths force researches to scrap trials
Roche’s reported success on lung cancer today came after another setback for their checkpoint Tecentriq.
Investigators at J&J were forced to scrap an early-stage combination of the PD-L1 drug with their Genmab-partnered Darazalex (daratumumab) for second-line lung cancer cases after it proved ineffective as well as possibly dangerous. And J&J went on to scrap an early-stage combination study using an in-house PD-1 with daratumumab for multiple myeloma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.